Has Ludmil Manov, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,619 in general payments to Ludmil Manov, MD across 218 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ludmil Manov, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ludmil Manov, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ludmil Manov, MD

Psychiatry · American Fork, UTNPI 1629098108

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 45.1% of the total. Among psychiatry clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,619in general payments, 2019–2025

Across 218 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$2K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$477
Vanda Pharmaceuticals Inc.$325
Johnson & Johnson$202
Supernus Pharmaceuticals, Inc.$163
AbbVie$112
plus $707 from 15 others

What the payments were for

Consulting fees$1003%
Food & beverage$3,47196%
Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	113	$1,634
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	12	$477
Vanda Pharmaceuticals Inc.	17	$325
Johnson & Johnson	11	$202
Supernus Pharmaceuticals, Inc.	9	$163
AbbVie	6	$112
Comsort, Inc	1	$100
Takeda Pharmaceuticals U.S.A., Inc.	13	$88
Corium, LLC	6	$78
E.r. Squibb & Sons, L.L.C.	4	$67
Lundbeck LLC	4	$66
Sunovion Pharmaceuticals Inc.	4	$56
Tris Pharma Inc	4	$54
Ironshore Pharmaceuticals Inc.	3	$43
Adlon Therapeutics L.p.	2	$36
Shire North American Group Inc	2	$32
Jazz Pharmaceuticals Inc.	2	$31
Neuronetics, Inc.	2	$17
Merck	1	$16
Alkermes, Inc.	1	$12
Arbor Pharmaceuticals, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

CAPLYTA$246
BRIDION$100

How this compares

$3,619 in reported general payments places this provider in the 90th percentile of 231 psychiatry providers in Utah.

See all psychiatry providers in Utah →

Medicare billing

Part B allowed, 2024

$13,646

Medicare patients

Services billed

118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Phenelzine Sulfate	15	$2,303
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	59	$1,659
Lurasidone Hcl	14	$1,503
Duloxetine Hcl	30	$1,436
Trazodone Hcl	61	$1,189
Gabapentin	23	$1,166
Aripiprazole	36	$923
Olanzapine	20	$819
Lamotrigine	35	$792
Quetiapine Fumarate	32	$749
Bupropion XlBupropion Hcl	20	$638
Clonazepam	70	$627
Divalproex Sodium ErDivalproex Sodium	12	$614
Sertraline Hcl	19	$504
Alprazolam	31	$402

Paid to pharmacies, not to this prescriber.

Other psychiatry in American Fork

Michael MeasomSlc$2.2M
Noel GardnerSalt Lake City$512K
Reid RobisonOrem$133K
Thomas RaynerProvo$60K
Trent HolmbergDraper$32K
Nathan CurrierRiverton$21K
Oliver McPhersonBountiful$20K
Frederick ReimherrSalt Lake City$18K
Lisa FraleighLogan$8K
Clark JohnsonSalt Lake City$7K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →